Assessment of Bone Mineral Density Decline in Prostate Cancer Patients Undergoing Hormonal Therapy

Introduction: The prostate cancer is a highly prevalent cancer in men, and enhanced screening and treatment have helped in earlier detection and greater longevity. However, due to complications, patients' quality of life has grown more crucial. Despite regional therapy, Prostate cancer naturally develops to metastasis, notably in the bone, increasing mortality and morbidity from skeletal-related events and necessitating operation or therapy. The objective of the article is to analyze the influence of various hormone therapies on bone mineral density, termed Bone Mineral Density(BMD) in individuals with prostate cancer. Methods: The research includes two groups, in Group A patients who have prostate cancer take the treatment named Luteinizing Hormone-Releasing Hormone agonists (LHRH), and for Group B patients, the treatment called anti-androgen hormonal therapy. It particularly analyses the impact of LHRH in Group A on anti-androgen medication in Group B. Results: A questionnaire was presented to the patients to gather data on several parameters such as medical information, and lifestyle behaviors. A paired t-test and multiple linear regression analyses were carried out using the SPSS software version 28, to investigate the impact of hormonal treatment on BMD results. Conclusion: The research found that age, duration of hormone therapy, BMI, and baseline BMD were significant indicators of BMD changes among patients with prostate cancer. The results suggest that group A, which was undergoing LHRH treatment, is more successful in maintaining BMD, compared to the group B, which emerged from anti-androgen therapy.